Background: Our previous study revealed that proline-rich tyrosine kinase 2 (Pyk2) is implicated in both anchorage-independent growth and anoikis resistance in lung cancer cells. This study aims to explore the expression and clinical significance of Pyk2 and its phosphorylated forms in non-small-cell lung cancer (NSCLC).
Lung cancer remains the most common type of cancer and the leading cause of cancer deaths worldwide, representing B29% and 26% of all male and female cancer deaths, respectively, in 2012 (Siegel et al, 2012) . Non-small-cell lung cancer (NSCLC), including adenocarcinoma (AC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC), is the most common subtype, representing B80% of all lung cancers (Petersen and Petersen, 2001; Collins et al, 2007 ) . Despite the existence of various established tumour biomarkers for early detection and new treatment modalities that include targeted therapy and immunotherapy to improve patients' therapeutic response and prognosis, the overall 5-year survival rate for NSCLC remains poor, still o15% (Siegel et al, 2012) . Therefore, it is crucial to understand the underlying molecular and cellular mechanisms mediating NSCLC progression and the process of metastasis, find effective tumour biomarkers for early diagnosis and provide potential therapeutic targets for improving the current treatment efficacy and overall survival of NSCLC patients.
Proline-rich tyrosine kinase 2 (Pyk2), also known as calciumdependent tyrosine kinase (CADTK), is a nonreceptor tyrosine kinase belonging to the FAK (focal adhesion kinase) family. The Pyk2 contains several tyrosine residues, including the major autophosphorylation site (Y402), which acts as the binding site for the SH2 domains of Src and Fyn, and the putative binding site for the SH2 domain of Grb2 (Y881) (Xiong et al, 1998) . The Pyk2 is demonstrated to be involved in several cellular functions, such as cell adhesion, motility, proliferation, apoptosis and the cell cycle (Guo et al, 1998; Blaukat et al, 1999; Avraham et al, 2000; Gelman, 2003) . Although one report showed that Pyk2 was expressed primarily in normal epithelial prostate tissue and benign prostatic hyperplasia but seldom in prostate cancer, acting as a tumoursuppressor gene (Stanzione et al, 2001) , other reports have shown that Pyk2 is highly expressed in neuroglioma, breast cancer and hepatocellular carcinoma and has prognostic significance in hepatocellular carcinoma (Lipinski et al, 2005; Sun et al, 2007; Behmoaram et al, 2008) . Our previous study has shown that Pyk2 was implicated in anchorage-independent growth and anoikis resistance in lung cancer cell lines , and another study also demonstrated that Pyk2 was upregulated in NSCLC and that it modulated the activity of ERK1/2 to promote the progression of NSCLC (Zhang et al, 2008) . Therefore, Pyk2 may play an important role in the development of lung cancer. However, the prognostic effect of Pyk2 expression, especially the phosphorylated forms of Pyk2 expression, in NSCLC and the molecular mechanism underlying this effect are still not fully understood.
The cancer stem cell (CSC) hypothesis suggests that a small proportion of the cells in a tumour mass, which has an indefinite proliferation and differentiation potential and give rise to phenotypically diverse cancer cells and neoplastic clones, contribute to tumour initiation, metastasis and recurrence. The limited subpopulation of CSCs in the mass of tumour cells and their unique phenotypes are considered to account for their resistance to conventional cancer therapies, resulting in tumour recurrence (Reya et al, 2001; Pardal et al, 2003) . Several CSC markers, such as CD133, ABCG2, ALDH1a1, Bmi-1, SOX2, Nanog and OCT-4, have been widely used to identify the limited numbers of CSCs in lung carcinoma (Eramo et al, 2008; Bertolini et al, 2009; Jiang et al, 2009; Chiou et al, 2010; Xiang et al, 2011) . As a previous study showed that Pyk2 had a compensatory function in promoting FAK-null mammary CSC tumourigenicity and metastatic activity (Fan and Guan, 2011) , we are interested in investigating whether Pyk2 might affect the CSC characteristics or other cellular functions of lung cancer cells.
In this study, we investigated the expression levels of Pyk2 and its two phosphorylated forms (pY402 and pY881) in primary NSCLC lesions, metastatic lymph nodes and brain lesions, and showed the positive relationship between high expression levels of Pyk2 and Pyk2[pY881] and the clinical outcomes of NSCLC using a statistical analysis. We also found for the first time that Pyk2 could upregulate the expression of ALDH1a1, ABCG2 and Bmi-1 and enhance the ability of colony formation in soft agar assay in A549 and H460 cells. Our data suggest that Pyk2 and Pyk2[pY881] may be potential prognostic factors and new therapeutic targets for the effective treatment of NSCLC.
MATERIALS AND METHODS
Antibodies. Mouse monoclonal antibody against ABCG2 (Cat. no. 3380) and rabbit antibodies against ALDH1a1 (Cat. no. 52492) were purchased from Abcam (Cambridge, UK). Mouse monoclonal antibody against GAPDH (sc-81545) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA (McShane et al, 2005) . The inclusion and exclusion criteria of the study are shown in Figure 1 . Briefly, two patient who suffered from an operation-related death and three patients who received induction of chemotherapy or radiation therapy were excluded. Four patients were lost to follow-up and specimens of nine patients were not available. A total of 128 patients (84 men and 44 women) were evaluated.
The age of the patients ranged from 33 to 82 years, and the mean age at the time of surgery was 59.4 years. Postsurgical pathologic stages of all the NSCLC patients were determined based on the seventh edition of the Union for International Cancer Control (UICC) Staging System for Lung Cancer. Histologically, 37 had squamous carcinoma and 91 patients had adenocarcinoma. Of the total 128 patients, 39, 34, 30 and 25 had stage I, II, III and IV tumours, respectively. The postsurgical survival time was calculated from the date of surgery to the time of cancer-related death or the most recent follow-up if the patient was alive. The median follow-up interval was 37.0 months (range: 3-70 months). The 5-year cumulative survival rate for all patients was 16%.
Tissue samples that had been histologically and clinically proofed were obtained from the archives of the Department of Sample Resources, Sun Yat-sen University Cancer Center. There were 15 paired freshly frozen lung carcinoma tissues and noncancerous tissues adjacent to cancer lesions from 15 NSCLC patients; 10 paraffin-embedded, noncancerous human lung tissues; and 128 paraffin-embedded NSCLC tissue samples. Consent was obtained from the patients, and the Institute Research Ethics Committee of Sun Yat-Sen University Cancer Center approved the clinical samples for research purposes.
Real-time RT-PCR analysis. The expression level of Pyk2 mRNA was detected using SYBR Green real-time reverse transcription-PCR (RT-PCR) (Invitrogen, Carlsbad, CA, USA). The total RNA was extracted from the paired carcinoma and noncancerous tissues of 15 NSCLC patients using TRIzol reagent (Life Technologies, Grand Island, NY, USA). Reactions were performed in triplicate in three independent experiments. Real-time PCR was conducted with a CFX connect Real-Time PCR Detection System (185-5200) (Invitrogen, Carlsbad, CA, USA). The housekeeping gene GAPDH was used as an internal control to normalise the variable expression levels of Pyk2. The sequences of the primers sequences are listed in Supplementary Table 1.
Western blotting. Western blotting analysis was performed as previously described . The membrane was incubated at 4 1C overnight with primary antibodies (as labelled in the figures) followed by incubation with horseradish peroxidaseconjugated goat anti-mouse or anti-rabbit IgG secondary antibody (1 : 3000) at room temperature for 1 h. The membranes were probed with mouse anti-GAPDH monoclonal antibody (1 : 4000) to confirm the equal loading of the samples. The signals were detected by enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech).
Immunohistochemistry. Immunohistochemistry was performed as previously described (Liao et al, 2007) . Where relevant, sections were incubated overnight at 4 1C with rabbit anti-Pyk2 . Staining intensity was graded according to the following criteria: 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellowish brown) and 3 (intense staining, brown). The staining index was calculated by multiplying the above two scores to yield a final score of 0, 1, 2, 3, 4, 6, 9 or 12. The tumours were finally determined to be of low expression (score p3) or high expression (score X4).
RT-PCR and plasmid construction. The total RNA extracts from the normal lung cell lines were prepared using TRIzol reagent (Life Technologies) according to the manufacturer's instructions. The RNA was then treated with RNA-free DNase, and 2.5 mg total RNA was used for cDNA synthesis with random hexamers. The primers used for the amplification of Pyk2 are listed in Supplementary Table 1 .
The full length of homo Pyk2 was subcloned into the vector pBabe. The pSuper-retro-constructs containing the Pyk2 short hairpin RNA (shRNA) were created by cloning the following 19-nt Pyk2-specific RNAi target sequences into a pSuper-retro construct: Pyk2 shRNA 1: 5 0 -GCTTCTATAGCAACAGCTT-3 0 ; Pyk2 shRNA 2: 5 0 -GGTCCTGAATCGTATTCTT-3 0 .
Cell culture and establishment of Pyk2 stably overexpressing and knockdown cell lines. Two poorly differentiated lung cancer cell lines, human lung adenocarcinoma cells (A549) and large cell human lung carcinoma cells (NCI-H460), were obtained from the American Type Cell Culture Collection (ATCC, Rockville, MD, USA). The cells were cultured in RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS), 100 IU ml À 1 streptomycin and 100 mg ml À 1 penicillin in a humidified 5% CO2 incubator at 37 1C. To establish stable cell lines, recombinant retroviruses expressing the vector pBabe, pBabe subcloned with Pyk2, pRETRO-SUPER and pRETRO-SUPER subcloned with Pyk2 shRNA 1 or Pyk2 shRNA 2 were generated and used to infect A549 and H460 cells as previously described (Brummelkamp et al, 2002; Kong et al, 2010; . The A549 and H460 cell populations expressing the desired plasmids were selected with 2 mg ml À 1 of puromycin (Sigma-Aldrich, St Louis, MO, USA) for 2 days. The successful overexpression and knockdown of Pyk2 were verified by western blotting.
Immunofluorescence analysis. Cells were plated for immunofluorescence on coverslips as described previously (Song et al, 2006) . Briefly, the cells were incubated overnight at 4 1C with primary antibodies against Pyk2, ABCG2, ALDH1a1 or Bmi-1 and then incubated in the dark for 30 min at room temperature with secondary goat antibodies against rabbit or mouse IgG (Invitrogen, Carlsbad, CA, USA). The coverslips were counterstained with DAPI and examined using an Olympus confocal imaging system (Olympus FV100, Olympus, Japan).
Anchorage-independent growth assay. Six-well plates were covered with a layer of 0.5% agar in medium supplemented with 20% FBS. Cells were prepared in 0.33% agar and seeded in triplicate, with a total number of 5 Â 10 3 cells in each well. The plates were incubated at 37 1C in a humid atmosphere of 5% CO 2 for 2 weeks with medium added every 3 days. At least three independent experiments were performed. Colonies were photographed between 10 and 14 days at an original magnification of Â 40 under a phase contrast microscope to count the colonies 450 mm in diameter.
Statistical analysis. The SPSS 16.0 statistical software package (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. The differences among variables were evaluated by w 2 analysis or two-tailed Student's t-tests. The data were all presented as the mean±s.e.m. unless otherwise indicated. The w 2 analysis and Fisher's exact tests were performed to analyse the correlations between Pyk2, Pyk2[pY881] expression and clinicopathologic characteristics. Bivariate correlations between the study's variables were evaluated using Spearman's rank correlation coefficients.
The postsurgical survival time was calculated from the date of surgery to the time of cancer-related death or the most recent follow-up if the patient was alive. Survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test to determine significance. The survival data of the prognostic factors were evaluated by univariate and multivariate Cox regression models. The P-values of p0.05 in all cases were considered to indicate a statistically significant result.
RESULTS

Expression of Pyk2, Pyk2
[pY402] and Pyk2[pY881] was upregulated in NSCLC tissues by real-time RT-PCR and western blotting analysis. To determine the mRNA and protein expression levels of Pyk2 in NSCLC lesions, real-time RT-PCR analysis and western blotting analysis were conducted in paired fresh frozen NSCLC tissues and adjacent noncancerous tissues from the same patient. Both the mRNA and protein levels of Pyk2 were found to be differentially overexpressed between the human NSCLC samples and the paired normal tissues adjacent to the tumours (Figure 2A and B). The protein levels of phosphorylated Pyk2 (pY402 and pY881) were also upregulated in cancerous tissue compared with noncancerous tissue using western blotting analysis ( Figure 2B and Supplementary Figure 1A) ; however, only weak pY402 expression was observed in NSCLC tissues. As shown in Figure 3 , Pyk2 was found to be overexpressed in the NSCLC lesions, metastatic lymph nodes and brain lesions ( Figure 3A , B, D-G). In contrast, Pyk2 was either undetectable or only marginally detectable in the noncancerous lung tissues of the adjacent section regions ( Figure 3B and C). Pyk2 protein was detected in 124 of 128 (97%) human NSCLC cases, and strong cytoplasmic staining of Pyk2 protein was detected in 70 (54.7%) tumours (Table 1) .
Overexpression of Pyk2 and
Similar to Pyk2, as shown in Figure 4 , Pyk2[pY881] was found to be overexpressed in primary NSCLC lesions, metastatic lymph nodes and brain lesions ( Figure 4A, Taken together, our data revealed that the Pyk2 protein expression level increases concurrently with NSCLC clinical metastasis, although it may not increase in the early tumour development stage. The expression of Pyk2[pY881] not only increases throughout the NSCLC progression and metastasis stages but is also associated with poor differentiation in the cases included in the present study.
Comparison of the Pyk2 and Pyk2[pY881] expression levels in primary NSCLC lesions and metastatic lymph nodes. The expression levels of Pyk2 and Pyk2[pY881] in the matched metastatic lymph nodes of 47 NSCLC patients were also evaluated, and the expression levels between the primary NSCLC lesions and metastatic LNs were compared. As shown in Supplementary As shown in Figure 5A , the length of survival time showed a statistically significant difference between the patients with high expression levels and the patients with low expression levels of Pyk2 (Po0.001), with the low Pyk2 expression group having a better survival. The cumulative 5-year survival rate was 26.0% in the low Pyk2 expression group, whereas it was only 6.0% in the high Pyk2 expression group. In light of the potential involvement of Pyk2 in the advanced NSCLC progression stage, we further analysed the patients' survival in terms of Pyk2 expression in the 47 matched metastatic lymph node tissues. As shown in Figure 5B , examination of the metastatic lymph nodes tissues revealed that patients with a high Pyk2 expression had a poor overall survival compared with patients expressing low Pyk2 (P ¼ 0.018). Furthermore, Pyk2 expression levels were still strongly correlated with patients' survival even after stratifying the patients based on their clinicopathologic features ( Figure 5C and D and Supplementary  Figure 2) . Moreover, patients with a high Pyk2 expression had poorer overall survival regardless of tumour differentiation, T stage and N stage. In addition, the overall survival showed a statistically significant difference between the high and low Pyk2 expression groups in the adenocarcinoma, M0 stage and late clinical stage (III þ IV) subgroups.
In Figure 6A , the length of the survival time was significantly different between patients with high and low expression levels of Pyk2[pY881] (Po0.001), with the high Pyk2[pY881] expression group having worse survival. The cumulative 5-year survival rate was 32.0% in the low Pyk2[pY881] expression group, whereas it was only 5.0% in the high Pyk2[pY881] expression group. Furthermore, the patients' survival in terms of the Pyk2[pY881] expression in the 47 corresponding metastatic lymph node tissues was analysed. As shown in Figure 6B , an examination of the metastatic lymph nodes tissues revealed that patients with high Pyk2[pY881] expression had poor overall survival compared with patients expressing low Pyk2[pY881] (P ¼ 0.005). In addition, the Pyk2[pY881] expression levels were still strongly correlated with patients' survival even after stratifying the patients based on their clinicopathologic features ( Figure 6C and D and Supplementary  Figure 3) . In particular, patients with high Pyk2[pY881] expression have poorer overall survival regardless of tumour histology, differentiation, T, N and M stage and clinical stage. Moreover, the overall survival showed a statistically significant difference between the high and low Pyk2[pY881] expression groups in the EGFR wild-type subgroup.
Univariate and multivariate analyses were conducted to determine whether the Pyk2 and Pyk2[pY881] expression levels are independent prognostic factors of NSCLC patients' outcomes. Both the Pyk2 and Pyk2[pY881] expression levels in the primary NSCLC tissues, as well as M and clinical stage, were recognised as independent prognostic factors when the Pyk2 and Pyk2[pY881] expression levels were analysed apart ( Table 2 ). The relative risks of Pyk2 and Pyk2[pY881] for the NSCLC patients' prognosis were 2.089 (95% CI: 1.346-3.241) and 3.086 (95% CI: 1.941-4.907), respectively. Taken together, our data suggest that Pyk2 and Pyk2[pY881] may represent novel and potentially useful biomarkers for the prognosis of NSCLC patients.
Pyk2 upregulates cancer stem cell marker expression and enhances transforming ability of NSCLC cells. As Pyk2 is a potent prognostic marker for NSCLC patients, we investigated its molecular mechanism in NSCLC cell lines. Interestingly, as shown in Figure 7A and B, CSC markers, such as ALDH1a1, ABCG2 and Bmi-1, were found to be upregulated at the protein level in Pyk2 stably overexpressing A549 and H460 cell lines. Furthermore, the protein levels of the CSC markers ALDH1a1, ABCG2 and Bmi-1 were downregulated in Pyk2 knockdown in the A549 and H460 cell lines. Immunofluorescence staining further confirmed this phenomenon (Supplementary Figure 4) . The above experiments suggest that Pyk2 can induce CSC marker expression in NSCLC cells.
We next used an anchorage-independent growth assay in soft agar to investigate the effect of Pyk2 on the transforming ability of NSCLC cells. As shown in Figure 7C and D, the knockdown of In the squamous carcinoma subtype, the patients' overall survival demonstrates no statistically significant difference between the high and low Pyk2 expression groups (P ¼ 0.139). In the adenocarcinoma subtype, patients with high Pyk2 expression show short overall survival times (Po0.001). The Pyk2 low expression: score p3; high expression: score X4. endogenous Pyk2 protein expression in the A549 and H460 cells caused a significant inhibition of their anchorage-independent growth, as indicated by the reduction of the colony size and colony number on soft agar (Po0.05), whereas the overexpression of endogenous Pyk2 in A549 and H460 cells caused significant promotion of their anchorage-independent growth. Therefore, these data indicate that Pyk2 can enhance the malignant transformation of NSCLC cells.
DISCUSSION
This study revealed that Pyk2 protein and phosphorylated Pyk2[pY881] protein were upregulated in primary NSCLC lesions and metastatic lymph nodes in comparison with normal lung tissues. Importantly, Pyk2 and Pyk2[pY881] protein expression levels were found to significantly correlate with the prognosis of NSCLC and were independent prognostic factors of NSCLC patients. The gain and loss study of Pyk2 function revealed that Pyk2 could upregulate the expression of ALDH1a1, ABCG2 and Bmi-1 and enhanced the ability of colony formation in soft agar assay in A549 and H460 cells. Our study suggests that Pyk2 and Pyk2[pY881] may represent novel predictive markers for the clinical outcomes of NSCLC.
Proline-rich tyrosine kinase 2 is a nonreceptor tyrosine kinase that plays different roles in the intracellular signalling pathways that regulate a number of biological processes, such as cell proliferation, differentiation, adhesion and migration, that have been shown to correlate with tumour development and aggression. A previous report has shown that the Pyk2 protein expression level was upregulated in NSCLC and that the higher expression and activation of Pyk2 might induce the modulation of ERK1/2 activity, leading to the progression of NSCLC (Zhang et al, 2008) . Our previous study has also shown that Pyk2 played a critical role in anchorage-independent growth and anoikis resistance in lung carcinoma cell lines . In this study, we confirmed that Pyk2 was upregulated in NSCLC and further investigated the relationship between the expression levels of Pyk2 protein in cancer tissues and patients' clinical outcomes, showing for the first time that Pyk2 is an independent predictive factor for the clinical prognosis of NSCLC. Our results were supported by a previous study that patients with higher levels of Pyk2 in hepatocellular carcinoma tissues had larger tumour size, advanced Edmonson grading and poor prognosis (Sun et al, 2007) .
In addition, we investigated whether the phosphorylated forms of Pyk2 play important roles in NSCLC progression. We thus chose Pyk2[pY402] and Pyk2[pY881] as two representative Pyk2 phosphorylation sites. However, Pyk2[pY402] protein expression in NSCLC tissues was low by both western blotting and immunohistochemistry assays, suggesting that the Pyk2[pY402] expression level in NSCLC tissues might be sufficiently low to escape detection with IHC analysis. The possibility that the negative result might be related to the valence of the rabbit antiPyk2[pY402] antibody also cannot be ruled out. Further research is needed to confirm our conjecture. Interestingly, a high level of Pyk2[pY881] protein expression in NSCLC tissues was closely associated with poorer differentiation; higher T, N and M stages; advanced clinical stage; and shorter survival times of the patients. Based on the multivariate analyses, Pyk2[pY881] was shown to be an independent predictive factor for the clinical outcomes of NSCLC. This study is the first to reveal that the phosphorylated form of Pyk2 is related to the clinical outcomes of cancer patients. Previous studies have shown that Pyk2 phosphorylated on Tyr881 provides a binding site for Grb2 to form the SHPS-1 signalling complex, thus leading to Erk1/2 (MAP kinase) activation and cell proliferation in response to IGF-I (Shen et al, 2010 ). It appears that Pyk2 phosphorylated on Tyr881 may be critical for its function in cell migration (Keogh et al, 2002) . Our former study has preliminarily shown that cell aggregation induces increased levels of the tyrosine phosphorylation of Pyk2 and promotes tumour cell anchorage-independent growth . This study further verifies that high expression levels of phosphorylated Pyk2[pY881] protein in lung carcinoma tissues are correlated with tumour differentiation and the prognosis of NSCLC patients. The underlying molecular mechanisms by which Pyk2[pY881] promotes NSCLC carcinogenesis and progression will be further investigated. It has been reported that Pyk2 is induced and involved in monocyte differentiation (Park et al, 2008) . In prostate cancer, Pyk2 seemed to have a role in the tumourigenesis, differentiation and cancer invasion, and Pyk2 could be a marker of prostate cell differentiation (Picascia et al, 2002) . However, more reports have shown that Pyk2 is highly expressed in neuroglioma, breast cancer and hepatocellular carcinoma (Lipinski et al, 2005; Sun et al, 2007; Behmoaram et al, 2008) . Until now, the correlation between the phosphorylated Pyk2 protein and the differentiation status in tumour cells has not been studied. Our study showed that high level of phosphorylated Pyk2[pY881] expression, but not Pyk2 expression, was strongly correlated with poor differentiation in lung cancer (P ¼ 0.003 and P ¼ 0.302, respectively). Consistently, phosphorylated Pyk2[pY881] was induced during epithelialmesenchymal transition (EMT) in mouse mammary NMuMG cells (Nakamura et al, 2001) . As EMT plays a major role during cancer invasion and metastases, it is worthwhile to further investigate whether phosphorylated Pyk2[pY881] could also induce EMT in lung cancer in the future.
A variety of G-protein-coupled receptors (GPCRs) are coupled with the mitogen-activated protein (MAP) kinase signalling cascade by the implication of the EGFR and the nonreceptor protein tyrosine kinases Src and Pyk2 (Della et al, 1997; Luttrell et al, 1999; Hackel et al, 1999; Carpenter, 1999) . A previous study also reveals that Pyk2 activation triggers the Src family kinase (SFK)/EGFR signalling pathway and cell motility after wounding sheets of epithelial cells (Block et al, 2010) . These findings suggest that there is an underlying interrelationship between EGFR and Pyk2. However, a statistical relationship between the mutation status of EGFR and the expression level of Pyk2 or Pyk2[pY881] was not detected by a w 2 analysis. This result may be ascribed to the limited number of the 51 NSCLC cases we analysed by roughly categorising the EGFR site mutation and amplification as an EGFR mutation subtype (37 patients). Owing to our limited tissue samples, the overall survival analyses were not significantly different between the high and low Pyk2 expression groups in squamous carcinoma (37 patients), EGFR wild-type (14 patients), EGFR mutationtype (37 patients) and M1 stage (25 patients) subgroups, and there was no statistically significant difference in the overall survival between the high and low Pyk2[pY881] expression groups in the EGFR mutation-type (37 patients) subgroup. Thus, a larger number of NSCLC cases is needed to yield a conclusive result. Besides, this is just a retrospective study, and a validation group as well as an independent group is needed to further confirm our study results. Finally, our gain and loss study of Pyk2 function revealed that Pyk2 could upregulate the expression of ALDH1a1, ABCG2 and Bmi-1 and enhance the ability of colony formation in soft agar assay in A549 and H460 cells. This is supported by a former study that Pyk2 has a compensatory function in promoting FAK-null mammary CSC tumourigenicity and metastatic activity with the PI3K/Akt signalling pathway as a major mediator (Fan and Guan, 2011) . This study represents the first time that a direct association between Pyk2 and CSC marker expression has been revealed. Further study is needed to investigate the interaction between Pyk2 and potential CSC signalling pathways. Considering the results of this study and of our previous study on Pyk2 in lung cancer , we conclude that Pyk2 induces the progression of NSCLC partially by the molecular mechanisms of enhancing the tumour-transforming ability, increasing CSC marker expression and inducing anchorage-independent growth and anoikis resistance.
CONCLUSIONS
We have demonstrated for the first time that Pyk2 is an independent predictive factor for the clinical prognosis of NSCLC and has a direct interaction with CSC marker expression. Pyk2 protein and its phosphorylated form (Pyk2[pY881]) were upregulated in primary NSCLC lesions and metastatic lymph nodes in comparison with those in normal lung tissues. The Pyk2 can upregulate CSC marker expression and enhance the transforming ability of NSCLC cells. Thus, Pyk2 and Pyk2[pY881] are potential prognostic factors and therapeutic targets for the effective treatment of NSCLC.
